Market Cap | 3.64M | P/E | - | EPS this Y | 98.00% | Ern Qtrly Grth | - |
Income | -17.91M | Forward P/E | -1.66 | EPS next Y | 70.90% | 50D Avg Chg | -32.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -76.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -94.00% |
Recommedations | 2.00 | Quick Ratio | 0.96 | Shares Outstanding | 17.27M | 52W Low Chg | 4.00% |
Insider Own | 0.04% | ROA | -207.95% | Shares Float | 17.26M | Beta | 0.47 |
Inst Own | 11.46% | ROE | -1,048.70% | Shares Shorted/Prior | 0.90M/175.77K | Price | 2.02 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 274,620 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 65,494 | Change | -3.81% |
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
HC Wainwright & Co. | Buy | Sep 6, 24 |
HC Wainwright & Co. | Buy | Aug 15, 24 |
HC Wainwright & Co. | Buy | May 29, 24 |
HC Wainwright & Co. | Buy | May 16, 24 |
HC Wainwright & Co. | Buy | Apr 16, 24 |
HC Wainwright & Co. | Buy | Apr 3, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Fitzgerald Thomas A | Chief Financial Offi.. Chief Financial Officer | Sep 28 | Buy | 0.51 | 49,350 | 25,168 | 56,318 | 10/02/23 |
Dudley Robert Michael | Chief Executive Offi.. Chief Executive Officer | Sep 28 | Buy | 0.51 | 98,000 | 49,980 | 180,262 | 10/02/23 |
Dudley Robert Michael | Chief Executive Offi.. Chief Executive Officer | Jun 20 | Buy | 2.6 | 18,607 | 48,378 | 82,262 | 06/22/23 |
Dudley Robert Michael | Chief Executive Offi.. Chief Executive Officer | Jun 09 | Buy | 2.76 | 19,000 | 52,440 | 912,114 | 06/13/23 |
Dudley Robert Michael | Chief Executive Offi.. Chief Executive Officer | Sep 14 | Buy | 1.15 | 20,000 | 23,000 | 893,114 | 09/16/22 |